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Abstract
Genetic risk factors for pain sensitivity may also play a role in susceptibility to chronic pain
disorders, in which subjects have low pain thresholds. The aim of this study was to determine if
proposed functional single nucleotide polymorphisms (SNPs) in the GTP cyclohydrolase (GCH1) and
μ opioid receptor (OPRM1) genes previously associated with pain sensitivity affect susceptibility to
chronic widespread pain (CWP). Pain data was collected using body manikins via questionnaire at
three time-points over a four year period from subjects aged 25-65 in the North-West of England
as part of a population based cohort study, EPIFUND. CWP was defined at each time point using
standard criteria. Three SNPs forming a proposed "pain-protective" haplotype in GCH1
(rs10483639, rs3783641 and rs8007267) and two SNPs in OPRM1  (rs1777971 (A118G) and
rs563649) were genotyped in cases with persistent CWP (CWP present at ≥2 time-points) and
controls who were pain-free at all time-points. The expectation-maximisation algorithm was used
to estimate haplotype frequencies. The frequency of the "pain-protective" (CAT - C allele of
rs10483639, A allele of rs3783641 and T allele of rs8007267) haplotype was compared to the
frequency of the other haplotypes between cases and controls using the χ2 test. Allele frequencies
and carriage of the minor allele was compared between cases and controls using χ2 tests for the
OPRM1 SNPs. The frequency of the proposed GCH1 "pain-protective" haplotype (CAT) did not
significantly differ between cases and controls and no significant associations were observed
between the OPRM1 SNPs and CWP. In conclusion, there was no evidence of association between
proposed functional SNPs, previously reported to influence pain sensitivity, in GCH1 and OPRM1
with CWP. Further evidence of null association in large independent cohorts is required to truly
exclude these SNPs as genetic risk factors for CWP.
Findings
The full aetiology of chronic widespread pain (CWP) is
unknown but evidence suggests that genetic risk factors
may contribute [1]. As a complex trait it is likely that mul-
tiple genes will be involved with each of them having a
small effect on the phenotype. Sensitivity to painful stim-
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uli has also been shown to be genetically influenced [2,3].
The relationship between CWP and pain sensitivity is
unclear. Clinic studies have shown increased pain sensi-
tivity in fibromyalgia patients using measures such as
thermal and mechanical stimuli and temporal summa-
tion [4-8]. However, it is unknown whether the relation-
ship between CWP and pain sensitivity is causal or
consequential. Genes which influence pain sensitivity
may also be important in susceptibility to chronic pain
syndromes such as CWP. Previous studies have reported
associations between known and purported functional
polymorphisms and pain sensitivity for two genes, GCH1
[9-11] and OPRM1[12,13].
GCH1 encodes GTP cyclohydrolase which is a pathway
synthesis enzyme for Tetrahydrobiopterin (BH4), a cofac-
tor essential in neurotransmitter synthesis which is up-
regulated in neuropathic and inflammatory pain [9]. In
2006, a haplotype comprised of 15 SNPs spanning GCH1
was reported to associate with a reduced hyperalgesic
response to a mechanical pain stimulus and also with
lower levels of lumbar pain following diskectomy [9],
thus implicating GCH1 as a potentially important gene in
both pain sensitivity and chronic pain. In 2007, Lotsch et
al demonstrated that this haplotype could be captured
with 100% specificity and sensitivity by genotyping only
three single nucleotide polymorphisms (SNPs);
rs10483639, rs3783641 and rs8007267, with the C, A and
T alleles of these three SNPs respectively forming the
"pain-protective" haplotype. Subsequent studies, how-
ever, have yielded conflicting results with some confirm-
ing the protective effect of the haplotype on pain
sensitivity [10,11] and others not [14]. Null associations
between the haplotype and pain severity following dental
surgery [14] and in subjects with pancreatitis [15] have
also been reported. Tegeder et al (2006) also reported
lower levels of GCH1  mRNA in subjects carrying the
"pain-protective" haplotype [9]. A subsequent study also
found that subjects homozygous for the CAT haplotype
had reduced levels of GCH1 mRNA as well as reduced lev-
els of BH4 compared to subjects not carrying the haplo-
type [10]. In addition, Zhang et al (2007) found that the
3' UTR SNP rs841, which is in LD with the "pain-protec-
tive" haplotype, also affects expression of the gene [16].
The second gene of interest, OPRM1, encodes the μ opioid
receptor which binds both exogenous and endogenous
opiates. The variant G allele of the non-synonymous SNP,
A118G (rs1799971) which changes asparagine to aspartic
acid, increases the ability of the receptor to bind β-endor-
phin and has been associated with increased pain thresh-
olds [12]. More recently, Shabalina et al (2009)
conducted a comprehensive analysis of the variation
within  OPRM1  and although they did not observe an
association between A118G and pain sensitivity they
found the minor (T) allele of rs563649 to be associated
with increased pain sensitivity. They also found that
rs563649 is located within the 5'UTR of an isoform of the
μ opioid receptor in a putative internal ribosome entry
site (IRES). In vitro, the T allele increased translational
activity through increased ribosome binding and lowered
mRNA levels suggesting the SNP may be functionally
important [13].
The aim of this study was to determine if the GCH1 "pain-
protective" haplotype and the OPRM1 SNPs, rs563649
and rs1799971 are associated with CWP in a UK popula-
tion-based cohort.
Subjects, aged 25-65 were recruited from 3 primary care
registers in the North-west of England into a prospective
population-based cohort study (EPIFUND, Epidemiology
of Functional Disorders). Pain data was collected at 3
time-points over a 4 year period via a postal survey. A
Linkage disequilibrium of the GCH1 haplotype Figure 1
Linkage disequilibrium of the GCH1 haplotype. SNPs 
genotyped and their position in GCH1 is shown with pair-
wise LD (coloured by D' and numbered with r2 values).Molecular Pain 2009, 5:56 http://www.molecularpain.com/content/5/1/56
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detailed pain questionnaire and body manikins were used
to ascertain CWP status using American College of Rheu-
matology Criteria (pain for ≥3 months in contra-lateral
body quadrants above and below the waist and in the
axial skeleton) at each time-point. DNA was obtained,
using buccal swab sampling, from 1189 subjects who par-
ticipated at all three time-points and had complete pain
data. From this study population, a nested case-control
study was conducted with cases being subjects who had
CWP for ≥2 time-points and controls were subjects who
were pain-free at all 3 time-points. There was a female pre-
ponderance (58%) in subjects included in the analysis
and the mean ± standard deviation age of subjects was 50
± 9.6 years old. The proportion of females did not signifi-
cantly differ between cases and controls (p > 0.05) and
cases were significantly older than controls (p < 0.01).
Ethnicity was not determined in EPIFUND; however, sub-
jects were recruited from a predominantly white Cauca-
sian geographic area.
The three SNPs in GCH1; rs10483639, rs3783641 and
rs8007267, which capture the pain protective haplotype
[17] and two SNPs in OPRM1; rs563649 and rs1799971
(A118G), were genotyped in all cases (n = 197) and all
controls (n = 197). Genotyping was carried out using
Sequenom MassArray technology. Pair-wise LD was exam-
ined using Haploview [18]. All SNPs were in Hardy-Wein-
berg Equilibrium and their genotyping success rate was
≥97%.
The genomic position of the three GCH1 SNPs and the
pair-wise LD between them in this UK population is
shown in Figure 1. Haplotype frequencies in the cases (N
= 164) and controls (N = 172) were estimated using the
Expectation-Maximisation algorithm and compared using
a χ2test in PLINK [19]. Allele frequencies were compared
between cases and controls for the OPRM1 SNPs using a
χ2 test. The effect of having one or two copies of the minor
allele compared to zero copies (dominant model) was
also tested using a χ2 test. Odds ratios (OR) and 95% con-
fidence intervals (95%CI) were calculated using logistic
regression. Analysis was conducted using STATA version
9.2.
Two common, GTC (76%) & CAT (17%); and two rare
(≤3%), CTC and CAC; GCH1 haplotypes were identified
in the population. There was no significant difference in
the overall distribution of haplotypes between cases and
controls (p = 0.488). The pain-protective (CAT) haplotype
was less frequent in cases (15%) compared to controls
(19%), although this was also non-significant (p = 0.129).
Concurrently the most common haplotype, GTC, showed
a non-significant (p = 0.190) increased frequency in cases
(81%) compared to controls (77%) (Table 1). This result
is in keeping with the findings of previous reports [14,15]
that did not replicate the findings of the initial study
which observed association between the haplotype and
both pain sensitivity and chronic pain [9].
Table 2: Results of analysis of OPRM1 SNPs with CWP
SNP Cases Controls OR (95%CI) p-value
N (%) N (%)
rs563649 Allele C 336 (92) 321 (90) 1
T 30 (8) 37 (10) 0.77 (0.45, 1.32) 0.321
Genotype CC 155 (85) 146 (82) 1
CT & TT 28 (15) 33 (18) 0.80 (0.46, 1.39) 0.425
rs1799971 Allele A 287 (90) 298 (90) 1
G 31 (10) 34 (10) 0.95 (0.55, 1.63) 0.834
Genotype AA 130 (82) 136 (82) 1
AG & GG 29 (18) 30 (18) 1.01 (0.58, 1.78) 0.967
Table 1: Results of haplotype analysis of GCH1 with CWP
Combination of SNPs Overall distribution
p-value
Haplotype Frequency of individual haplotypes
Cases Controls p-value
rs10483639 - rs3783641 - rs8007267 0.488 GTC 0.81 0.77 0.190
CAT 0.15 0.19 0.129
CTC 0.03 0.02 0.714
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There was no evidence of association with CWP for either
of the OPRM1 SNPs, although rs563649 showed a trend
towards a protective effect of the T allele (Table 2). This is
in contrast to the findings of Shabalina et al (2009) who
found the T allele to be associated with increased pain
scores [13].
The aim of this study was to determine if putative func-
tional SNPs reported to influence pain sensitivity are
genetic predictors of CWP susceptibility. There was no evi-
dence of a significant association between the GCH1
"pain-protective" haplotype or the two SNPs in OPRM1
and CWP. It should be noted that sample size in the stud-
ies of pain sensitivity and chronic pain conducted on
these two genes were relatively small with the maximum
being N = 632. Equally in this study the sample size was
modest therefore the decreased prevalence of the GCH1
CAT haplotype in subjects with persistent CWP compared
to pain-free controls may not have reached significance in
this study due to limited power. Further investigation of
this relationship in larger independent cohorts is there-
fore warranted.
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